Morning Overview on MSN
A new daily pill beat oral Ozempic for weight loss and blood sugar in a major diabetes trial
Eli Lilly’s once-daily oral pill orforglipron outperformed oral semaglutide in reducing blood sugar and body weight over 52 ...
Phase 3 clinical trial results (TRANSCEND-T2D-1) published in The Lancet report that retatrutide, an investigational ...
Retatrutide is designed to control appetite and blood sugar but also increase body’s energy expenditure, unlike other drugs ...
A major new study, published today in The Lancet Diabetes & Endocrinology has shown that cortisol levels in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results